Home | Neuromuscular | Duchenne muscular dystrophy (DMD) | Congress activities | Child Neurological Society (CNS) Annual Meeting | CNS 2019 poster: Phase 2 trials to assess production of dystrophin protein in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren

CNS 2019 poster: Phase 2 trials to assess production of dystrophin protein in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren

The study design of two phase 2 clinical studies examining a mutation-specific DMD therapy is presented in our poster from CNS 2019

  • The objectives and primary and secondary outcome measures of two interventional phase 2 studies: Study 045 (NCT03648827), a trial examining the percentage change in levels of dystrophin from baseline in ambulatory treatment-naïve boys with nmDMD after treatment with a mutation-specific DMD therapy for 40 weeks (completed 30 October 2020); and Study 046 (NCT03796637) investigating the quantitative change in levels of dystrophin in ambulatory nmDMD subjects as measured by electrochemiluminescence (ECL) receiving a mutation-specific DMD treatment for ≥9 months (completed 24 May 2019)

▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

Registration
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

    *
    *
  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

GL-AADC-0551 | March 2021
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.